Bio-Rad Laboratories Still Hampered By Underwhelming Core Growth
Source: SeekingAlpha
2026-01-22 13:05:49 ET
Bio-Rad's ( BIO ) ( BIO.B ) management has been taking steps to improve its long-term core growth prospects, but it takes time for those steps to translate into real results. Meanwhile, the company has to deal with challenging end-market conditions, including considerable funding uncertainties for academic labs and biotechs, as well as global tariffs....
Read the full article on Seeking Alpha
For further details see:
Bio-Rad Laboratories Still Hampered By Underwhelming Core Growth
Qiagen N.V.
NASDAQ: QGEN
QGEN Trading
0.31% G/L:
$43.21 Last:
1,006,252 Volume:
$43.69 Open:
QGEN Latest News
March 10, 2026 05:05:00 pm
QIAGEN Receives U.S. Clearance for Gastrointestinal Panels on Fully Automated QIAstat-Dx Rise Syndromic Testing System
QGEN Stock Data
$10,633,318,293
203,932,295
N/A
22
N/A
Biotechnology & Life Sciences
Healthcare
NL
Venlo
